Thurston Springer Miller Herd & Titak Inc. Purchases 2,928 Shares of Cencora, Inc. (NYSE:COR)

Thurston Springer Miller Herd & Titak Inc. grew its position in Cencora, Inc. (NYSE:COR - Free Report) by 71.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,048 shares of the company's stock after purchasing an additional 2,928 shares during the period. Thurston Springer Miller Herd & Titak Inc.'s holdings in Cencora were worth $1,583,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in COR. Park Avenue Securities LLC grew its position in Cencora by 37.0% in the 4th quarter. Park Avenue Securities LLC now owns 11,690 shares of the company's stock worth $2,627,000 after purchasing an additional 3,156 shares in the last quarter. Kathmere Capital Management LLC grew its holdings in shares of Cencora by 14.6% in the fourth quarter. Kathmere Capital Management LLC now owns 2,091 shares of the company's stock valued at $470,000 after acquiring an additional 266 shares in the last quarter. Board of the Pension Protection Fund purchased a new stake in shares of Cencora during the fourth quarter valued at approximately $989,000. Fifth Third Wealth Advisors LLC lifted its holdings in Cencora by 11.8% during the fourth quarter. Fifth Third Wealth Advisors LLC now owns 1,958 shares of the company's stock worth $440,000 after acquiring an additional 206 shares during the period. Finally, Oak Thistle LLC bought a new stake in Cencora during the fourth quarter worth $455,000. 97.52% of the stock is owned by institutional investors.

Cencora Price Performance

NYSE COR traded down $2.31 during trading hours on Wednesday, hitting $237.74. The company had a trading volume of 1,186,513 shares, compared to its average volume of 1,303,101. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. The firm has a market capitalization of $45.95 billion, a price-to-earnings ratio of 31.66, a PEG ratio of 1.54 and a beta of 0.49. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $253.27. The firm has a 50 day simple moving average of $237.79 and a 200 day simple moving average of $233.67.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were paid a dividend of $0.55 per share. The ex-dividend date was Friday, November 15th. This represents a $2.20 annualized dividend and a yield of 0.93%. This is a boost from Cencora's previous quarterly dividend of $0.51. Cencora's payout ratio is currently 29.29%.

Analysts Set New Price Targets

COR has been the subject of several research analyst reports. StockNews.com lowered Cencora from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 20th. Leerink Partners lowered their price objective on shares of Cencora from $277.00 to $275.00 and set an "outperform" rating on the stock in a research report on Monday, October 7th. UBS Group lifted their price target on shares of Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Barclays upped their price target on Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. Finally, Robert W. Baird lifted their price objective on Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $275.60.

Insider Buying and Selling

In related news, EVP Silvana Battaglia sold 1,678 shares of the business's stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. The trade was a 7.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 21,509 shares of the firm's stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total value of $5,208,619.44. Following the completion of the sale, the chairman now directly owns 306,752 shares in the company, valued at approximately $74,283,064.32. The trade was a 6.55 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 94,696 shares of company stock valued at $22,862,734. Company insiders own 15.80% of the company's stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.